These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9232607)

  • 1. Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation.
    Rubenstein M; Chou P; Mirochnik Y; Guinan P
    Med Oncol; 1997 Mar; 14(1):23-9. PubMed ID: 9232607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
    Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
    Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2007; 24(4):372-8. PubMed ID: 17917084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
    Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
    Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2008; 25(2):182-6. PubMed ID: 17972023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
    Rubenstein M; Tsui P; Guinan P
    Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):515-8. PubMed ID: 17136230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides.
    Rubenstein M; Mirochnik Y; Chou P; Guinan P
    Methods Find Exp Clin Pharmacol; 1998 Dec; 20(10):825-31. PubMed ID: 10091218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
    Rubenstein M; Hollowell CM; Guinan P
    Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer.
    Rubenstein M; Anderson KM; Tsui P; Guinan P
    Med Hypotheses; 2006; 67(6):1375-80. PubMed ID: 16870352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.
    Rubenstein M; Hollowell CM; Guinan P
    Med Oncol; 2010 Dec; 27(4):1212-8. PubMed ID: 19937163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
    Rubenstein M; Tsui P; Guinan P
    Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
    Rubenstein M; Guinan P
    In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H; Tolcher A; Gleave ME
    J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bax expression remains unchanged following antisense treatment directed against BCL-2.
    Rubenstein M; Hollowell CM; Guinan P
    Med Oncol; 2011 Sep; 28(3):852-8. PubMed ID: 20422317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
    Rubenstein M; Hollowell CM; Guinan P
    In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
    Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.
    Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
    Med Oncol; 2003; 20(1):29-35. PubMed ID: 12665682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.